New compounds

Abstract

The present invention provides organic compounds of the following structure; A-L1-B-C-D-L2-E that are useful for treating or preventing conditions or disorders associated with DGAT1 activity in animals, particularly humans.

1 - 37 . (canceled) 
     
     
         38 . A compound as represented by figure “B”: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof wherein:
 A is a substituted or unsubstituted alkyl, cycloalkyl, aryl, or heterocyclyl group, 
 L1 is selected from the group consisting of:
 an amine group —NH— 
 a substituted amine group of the formula —N(CH 3 )—, —CH 2 —NH— or —CH 2 —CH 2 —NH—, 
 an amide group —C(O)—NH—, 
 a sulphonamide group —S(O) 2 —NH—, or 
 a urea group —NHC(O)—NH—, 
 
 B is a substituted or unsubstituted, monocyclic, 5- or 6-membered divalent heteroaryl group, 
 C is a substituted or unsubstituted divalent phenyl group, 
 L2 is selected from the group consisting of:
 a single bond, 
 a divalent residue having the following structure:
   —[R 1 ] a —[R 2 ] b —[C(O)] c —[N(R 3 )] d —[R 4 ] e —[R 5 ] f —
 
 
 wherein 
 a is 0 or 1, 
 b is 0or 1, 
 c is 0 or 1, 
 d is 0or 1, 
 e is 0 or 1, 
 f is 0 or 1, 
 with the proviso that (a+b+c+d+e+f)>0, and c=1 if d=1, 
 R 1 , R 2 , R 4  and R 5 , which can be the same or different, are a substituted or unsubstituted divalent alkyl, cycloalkyl, alkenyl, alkynyl, alkylene, aryl or heterocyclyl residue, 
 R 3  is H or hydrocarbyl, 
 or R 3  and R 4  form together with the nitrogen atom to which they are attached a 5- or 6-membered heterocycloalkyl group, 
 with the proviso that R 1  and R 2  are not both alkyl if c=1 and d=e=f=0 and the carbonyl carbon atom is attached to the moiety E, 
 an alkylidenyl group which is linked to the moiety D via a double bond, and 
 
 E is selected from the group consisting of:
 a sulphonic acid group and derivatives thereof, 
 a carboxyl group and derivatives thereof, wherein the carboxyl carbon atom is attached to L2, 
 a phosphonic acid group and derivatives thereof, 
 an alpha-keto hydroxyalkyl group, 
 a hydroxyalkyl group wherein the carbon atom bonded to the hydroxyl group is further substituted with one or two trifluoro-methyl groups, 
 a substituted or unsubstituted five-membered heterocyclyl residue having in the ring at least two heteroatoms and at least one carbon atom, wherein
 the at least one carbon atom of the ring is bonded to two heteroatoms; 
 at least one of the heteroatoms to which the carbon atom of the ring is bonded is a member of the ring; 
 and at least one of the heteroatoms to which the carbon atom of the ring is bonded or at least one of the heteroatoms of the ring is bearing a hydrogen atom; 
 
 
 
         with the provisos that
 E is not a carboxamide group if L2 comprises an amide group, 
 L2 is not a divalent N-methyl piperidinyl group if the moiety E is a pyridinyl-1,2,4-triazolyl group. 
 
       
     
     
         39 . The compound according to  claim 38 , wherein the divalent residue —[R 1 ] a —[R 2 ] b —[C(O)] c —[N(R 3 )] d —[R 4 ] e —[R 5 ] f — is selected from the group consisting of:
 a divalent alkyl group having from 1 to 4 carbon atoms 
 a divalent alkenyl group having from 2 to 3 carbon atoms 
 a —C(O)— group 
 a —C(O)—[R 4 ] e —R 5 — group wherein
 e is 0 and R 5  is selected from the group consisting of a divalent substituted or unsubstituted C 1 -C 4  alkyl group, C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, or 
 e is 1, R 4  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group, and R 5  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 
 a —R 1 —R 2 — group, wherein R 1  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group and R 2  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 a —C(O)—NH— group, 
 a —(CH 2 ) 1-3 —C(O)—NH—(CH 2 ) 1-3 — group, 
 a —C(O)—NH—R 4 — group, wherein R 4  is selected from a divalent substituted or unsubstituted C 1-7  alkyl group, cyclohexyl group or cyclopentyl group, 
 a —C(O)—N(R 3 )—R 4 — group, wherein R 3  and R 4  and the N-atom together form a pyrrolidine ring or a piperidine ring, or a pharmaceutically acceptable salt thereof. 
 
     
     
         40 . The compound according to  claim 38 , wherein the alkylidenyl group is ═CH—, or a pharmaceutically acceptable salt thereof. 
     
     
         41 . The compound according to  claim 38 , wherein the L1 group is an amine group —NH—, or a pharmaceutically acceptable salt thereof. 
     
     
         42 . The compound according to  claim 38 , wherein the L1 group is an amide group —C(O)NH— or —NHC(O)—, or a pharmaceutically acceptable salt thereof. 
     
     
         43 . The compound according to  claim 38 , wherein the carboxyl group or the derivative thereof representing the moiety E is selected from the group consisting of:
 a COOH group,   a carboxylic ester group,   a carboxamide group, or a pharmaceutically acceptable salt thereof.   
     
     
         44 . The compound according to  claim 38 , wherein the sulphonic acid group or the derivative thereof representing moiety E is selected from the group consisting of:
 a —S(O) 2 —OH group,   a —S(O) 2 —NHR 6  group, wherein R 6  is selected from hydrogen, a C 1 -C 8  alkyl group, a cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclyl group, or a carboxylic acid ester group, or a pharmaceutically acceptable salt thereof.   
     
     
         45 . The compound according to  claim 38 , wherein the 5-membered heterocyclyl residue representing moiety E is selected from the group consisting of:
 a tetrazole residue,   a triazole residue,   an oxadiazole residue,   a thiadiazole residue,   a diazole residue,   an oxazole residue,   a thiazole residue,   an oxathiadiazole residue, the heterocyclyl residue optionally having one or more substituents selected from an oxo group, a hydroxyl group and/or a thiol group, or a pharmaceutically acceptable salt thereof.   
     
     
         46 . The compound according to  claim 38  of formula: 
       
         
           
           
               
               
           
         
         wherein:
 B is selected from the group consisting of substituted or unsubstituted pyridine, substituted or unsubstituted pyridazine, substituted or unsubstituted pyrimidine, substituted or unsubstituted pyrazine, and substituted or unsubstituted oxazole, 
 L1 is selected from the group consisting of —NH—, —C(O)NH— and —NHC(O)—, 
 A is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl group, 
 -L2- is a divalent residue:
   —[R 1 ] a —[R 2 ] b —[C(O)] c —[N(R 3 )] d —[R 4 ] e —[R 5 ] f —
 
 
 
         selected from the group consisting of:
 a divalent alkyl group having from 1 to 4 carbon atoms 
 a divalent alkenyl group having from 2 to 3 carbon atoms 
 —C(O)— 
 —C(O)—[R 4 ] e —R 5 —, wherein
 e is 0 and R 5  is selected from the group consisting of a divalent substituted or unsubstituted C 1 -C 4  alkyl group, C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, or 
 e is 1, R 4  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group, and R 5  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 
 —R 1 —R 2 —, wherein R 1  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group and R 2  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 —C(O)—NH—, 
 —(CH 2 ) 1-3 —C(O)—NH—(CH 2 ) 1-3 —, 
 —C(O)—NH—R 4 —, wherein R 4  is selected from a divalent substituted or unsubstituted C 1-7  alkyl group, cyclohexyl group or cyclopentyl group, 
 —C(O)—N(R 3 )—R 4 —, wherein R 3  and R 4  and the N-atom together form a pyrrolidine ring or a piperidine ring, 
 
         E is selected from the group consisting of:
 COOH, 
 a carbocylic ester, 
 a carboxamide, 
 —S(O) 2 —OH, 
 —S(O) 2 —NHR 6 , wherein R 6  is selected from hydrogen, a C 1 -C 8  alkyl group, a cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclyl group, or a carboxylic acid ester group, or a pharmaceutically acceptable salt thereof. 
 
       
     
     
         47 . The compound of Formula I: 
       
         
           
           
               
               
           
         
         A is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl, 
         E′ is -L2-E, 
         -L2- is a divalent residue:
   —[R 1 ] a —[R 2 ] b —[C(O)] c —[N(R 3 )] d —[R 4 ] e —[R 5 ] f —
 
 
         selected from the group consisting of:
 a divalent alkyl group having from 1 to 4 carbon atoms 
 a divalent alkenyl group having from 2 to 3 carbon atoms 
 —C(O)—, 
 —C(O)—[R 4 ] e —R 5 —, wherein
 e is 0 and R 5  is selected from the group consisting of a divalent substituted or unsubstituted C 1 -C 4  alkyl group, C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, or 
 e is 1, R 4  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group, and R 5  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 —R 1 —R 2 —, wherein R 1  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group and R 2  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 —C(O)—NH—, 
 —(CH 2 ) 1-3 —C(O)—NH—(CH 2 ) 1-3 —, 
 —C(O)—NH—R 4 —, wherein R 4  is selected from a divalent substituted or unsubstituted C 1-7  alkyl group, cyclohexyl group or cyclopentyl group, 
 —C(O)—N(R 3 )—R 4 —, wherein R 3  and R 4  and the N-atom together form a pyrrolidine ring or a piperidine ring, 
 
 E is selected from the group consisting of:
 COOH, 
 a carbocylic ester, 
 a carboxamide, 
 —S(O) 2 —OH, 
 —S(O) 2 —NHR 6 , wherein R 6  is selected from hydrogen, a C 1 -C 8  alkyl group, a cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclyl group, or a carboxylic acid ester group, or pharmaceutically acceptable salts, prodrugs, stereoisomers, crystalline forms, or polymorphs thereof. 
 
 
       
     
     
         48 . The compound according to  claim 47  of Formula II: 
       
         
           
           
               
               
           
         
         A is substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclyl, 
         E′ is -L2-E, 
         -L2- is a divalent residue:
   —[R 1 ] a —[R 2 ] b —[C(O)] c —[N(R 3 )] d —[R 4 ] e —[R 5 ] f —
 
 
         selected from the group consisting of:
 a divalent alkyl group having from 1 to 4 carbon atoms 
 a divalent alkenyl group having from 2 to 3 carbon atoms 
 —C(O)—, 
 —C(O)—[R 4 ] e —R 5 —, wherein
 e is 0 and R 5  is selected from the group consisting of a divalent substituted or unsubstituted C 1 -C 4  alkyl group, C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, or 
 e is 1, R 4  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group, and R 5  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 
 —R 1 —R 2 —, wherein R 1  is a divalent substituted or unsubstituted C 1 -C 4  alkyl group and R 2  is a divalent substituted or unsubstituted C 4 -C 8  cycloalkyl group, phenyl group or 5- or 6-membered heterocyclyl group, 
 —C(O)—NH—, 
 —(CH 2 ) 1-3 —C(O)—NH—(CH 2 ) 1-3 —, 
 —C(O)—NH—R 4 —, wherein R 4  is selected from a divalent substituted or unsubstituted C 1-7  alkyl group, cyclohexyl group or cyclopentyl group, 
 —C(O)—N(R 3 )—R 4 —, wherein R 3  and R 4  and the N-atom together form a pyrrolidine ring or a piperidine ring, 
 
         E is selected from the group consisting of:
 COOH, 
 a carbocylic ester, 
 a carboxamide, 
 —S(O) 2 —OH, 
 —S(O) 2 —NHR 6 , wherein R 6  is selected from hydrogen, a C 1 -C 8  alkyl group, a cycloalkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclyl group, or a carboxylic acid ester group, or pharmaceutically acceptable salts, prodrugs, stereoisomers, crystalline forms, or polymorphs thereof. 
 
       
     
     
         49 . The compound of  claim 47 , wherein A is selected from substituted or unsubstituted phenyl, substituted or unsubstituted pyridine, substituted or unsubstituted cyclohexyl, substituted or unsubstituted isoxazole, substituted or unsubstituted oxadiazole, or substituted or unsubstituted pyrazole, and a pharmaceutically acceptable salt thereof. 
     
     
         50 . The compound of  claim 47 , wherein E′ is —C(O)OH, —CH 2 —C(O)OH, —CH 2 — heterocyclyl, or a pharmaceutically acceptable salt thereof. 
     
     
         51 . The compound of  claim 38 , selected from the group consisting of:
 (4-{4-[2-(3-Fluorophenylamino)-pyrimidin-5-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(2-Phenylaminopyrimidin-5-yl)phenyl]-cyclohexyl}-acetic acid,   (4-{4-[2-(3-Methoxyphenylamino)-thiazol-4-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(3-Fluorophenylamino)-thiazol-4-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(2-Chlorophenylamino)-thiazol-4-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(3-Cyanophenylamino)-thiazol-4-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(3-Trifluoromethylphenylamino)-thiazol-4-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(3-Fluorophenylamino)-thiazol-4-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4′-[2-(3-Chloro-phenylamino)-oxazol-5-yl]-biphenyl-4-yl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Chloro-phenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-methylphenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Trifluoromethylphenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Methoxyphenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(2-Fluorophenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(2-Methoxyphenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(2-Methoxyphenylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(Pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(5-Phenylaminopyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[5-(5-Cyanopyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Trifluoromethylpyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(4-Trifluoromethylphenylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Methylpyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Trifluoromethylpyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid methyl ester,   (4-{4-[5-(5-Chloropyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Methoxypyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Fluoropyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Acetylaminopyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(3-Methoxy-5-phenylamino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   {4-[4-(3-Methoxy-5-(3-fluorophenyl)amino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   {4-[4-(3-Methoxy-5-(4-trifluoromethyl-phenyl)amino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   {4-[4-(3-Methoxy-5-(3-chlorophenyl)amino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[5-(3-Fluoro-phenylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(3-Chloro-phenylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(1-Methyl-1H-pyrazol-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Fluoro-6-methoxy-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(Isoxazol-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Chloro-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Fluoro-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(6-m-Tolylamino-pyridazin-3-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[6-(3-Trifluoromethyl-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Methoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Cyano-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(2-Fluoro-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(4-Chloro-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(6-p-Tolylamino-pyridazin-3-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[6-(4-Trifluoromethyl-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Chloro-4-methoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Chloro-2-methyl-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(6-Phenylamino-pyridazin-3-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[6-(3-Chloro-2-methoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(2-Methoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(4-Methoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(4-Trifluoromethoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(4-Fluoro-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(6-Amino-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(Methyl-m-tolyl-amino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{6-[(3-Chloro-phenyl)-methyl-amino]-pyridazin-3-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{6-[(3-Methoxy-phenyl)-methyl-amino]-pyridazin-3-yl}-phenyl)-cyclohexyl]-acetic acid,   (4-{4-[6-(2-Methyl-6-trifluoromethyl-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(3-Chloro-2-methoxy-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (1S,2R)-2-{4-[6-(3-Chloro-phenylamino)-pyridazin-3-yl]-benzoylamino}-cyclohexanecarboxylic acid,   4-{4-[6-(3-Trifluoromethyl-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexanecarboxylic acid,   2-(4-{4-[6-(3-Chloro-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetamide,   (6-{4-[4-(2H-Tetrazol-5-ylmethyl)-cyclohexyl]-phenyl}-pyridazin-3-yl)-(6-trifluoromethyl-pyridin-3-yl)-amine,   3-(4-{4-[6-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexylmethyl)-4H-[1,2,4]oxadiazol-5-one,   (4-{4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-ylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[4-Methyl-6-(4-trifluoromethyl-phenylamino)-pyridazin-3-yl]-phenyl}-cyclohexyl)-acetic acid   (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyrazin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(2,2-Dimethyl-propionylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(Benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[6-(6-Methoxy-pyridin-3-ylamino)-5-methyl-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-Fluoro-6-(6-methoxy-pyridin-3-ylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   Oxo-(4-{4-[6-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(5-Acetylamino-pyridin-2-yl)-phenyl]cyclohexyl}-acetic acid,   (4-{4-[5-(3-Trifluoromethyl-benzoylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(Pyridine-2-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[3-(4-Trifluoromethoxy-phenyl)-ureido]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[3-(2-Trifluoromethyl-phenyl)-ureido]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   (4-{4-[5-(3-o-Tolyl-ureido)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(1-Methyl-1H-indole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(1H-Indole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(Pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(6-Methyl-pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Bromo-pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Chloro-6-methoxy-pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Isobutyl-isoxazole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(3-tert-Butyl-1-methyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-tert-Butyl-1H-pyrazole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Isopropyl-isoxazole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   {4-[4-(5-Isobutoxycarbonylamino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   [4-(4-{5-[((S)-5-Oxo-pyrrolidine-2-carbonyl)amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   (4-{4-[5-(4-Fluoro-3-trifluoromethyl-benzoylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(4-Trifluoromethyl-benzoylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(6-Trifluoromethyl-pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   (4-{4-[5-(3-Fluoro-5-trifluoromethyl-benzoylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(Tetrahydro-pyran-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Bromo-2-methoxy-pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(1,5-Dimethyl-1H-pyrazole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Methoxy-1H-indole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(2,5-Dimethyl-1H-pyrrole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(1-Methyl-5-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   {4-[4-(5-{[4-(Morpholine-4-sulfonyl)-1H-pyrrole-2-carbonyl]-amino}-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[5-(2-Fluoro-2-methyl-propionylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid methyl ester,   (4-{4-[5-(2-Methyl-2-pyrazol-1-yl-propionylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(5-Isopropyl-isoxazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(1-Methyl-3-trifluoromethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Cyclopropyl-isoxazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(5-Cyclopropyl-isoxazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid methyl ester,   [4-(4-{5-[(5-Cyclopropyl-isoxazole-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   [4-(4-{5-[(6-Methoxy-pyridine-3-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   (4-{4-[5-(2,2-Dimethyl-butyrylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(2-Methoxy-2-methyl-propionylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[(1,5-Dimethyl-1H-pyrazole-4-carbonyl)-amino]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   (4-{4-[5-(Tetrahydro-pyran-4-yloxycarbonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   {4-[4-(5-Cyclopropylmethoxycarbonylamino-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[5-(Tetrahydro-furan-2-ylmethoxycarbonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(Tetrahydro-pyran-2-ylmethoxycarbonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(3-Methyl-oxetan-3-ylmethoxycarbonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(Tetrahydro-pyran-4-ylmethoxycarbonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(2-Methyl-pyridin-3-ylmethoxycarbonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   [4-(4-{5-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-pyridin-2-yl}-phenyl)-cyclohexyl]-acetic acid,   {4-[4-(5-Isopropylcarbamoyl-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   {4-[4-(6-Carbamoyl-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   {4-[4-(6-Isopropylcarbamoyl-pyridin-2-yl)-phenyl]-cyclohexyl}-acetic acid,   (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylcarbamoyl)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(4-Trifluoromethyl-benzenesulfonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(3-Trifluoromethyl-benzenesulfonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(1,2-Dimethyl-1H-imidazole-4-sulfonylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Fluoro-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Isopropoxy-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Bromo-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(2-Methoxy-pyrimidin-5-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Methylsulfanyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-([1,2,4]Triazin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(2-Dimethylamino-pyrimidin-5-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Methylsulfanyl-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(3,5-Difluoro-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid methyl ester,   (4-{4-[5-(5-Chloro-6-methoxy-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Fluoro-4-methyl-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(3-Chloro-5-methyl-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Difluoromethyl-6-methoxy-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Methanesulfonyl-pyridin-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[3-Fluoro-5-(6-trifluoromethyl-pyridin-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(1H-Benzoimidazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Trifluoromethyl-[1,3,4]oxadiazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Methyl-benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(2-Methyl-5-trifluoromethyl-2H-pyrazol-3-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(6-Chloro-benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid methyl ester,   (4-{4-[5-(6-Chloro-benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-Chloro-6-methoxy-benzooxazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[5-(5-tert-Butyl-[1,3,4]oxadiazol-2-ylamino)-pyridin-2-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(6-Trifluoromethyl-pyridin-3-ylamino)-pyrimidin-5-yl]-phenyl}-cyclohexyl)-acetic acid,   (4-{4-[2-(5-Chloro-pyridin-2-ylamino)-pyrimidin-5-yl]-phenyl}-cyclohexyl)-acetic acid   (4-{4-[6-(2-Methyl-6-trifluoromethyl-pyridin-3-ylamino)-pyridin-3-yl]-phenyl}-cyclohexyl)-acetic acid, or a pharmaceutically acceptable salt thereof.   
     
     
         52 . A pharmaceutical composition, comprising:
 the compound according to  claim 38 , and   a pharmaceutical acceptable carrier or excipient.   
     
     
         53 . A method for treating conditions or disorders associated with DGAT1 activity, comprising:
 administering to a subject a compound having the following structure
   A-L1-B-C-D-L2-E 
   wherein:
 A is a substituted or unsubstituted alkyl, cycloalkyl, aryl, or heterocyclyl group, 
 L1 is selected from the group consisting of:
 an amine group —NH— 
 a substituted amine group of the formula —N(CH 3 )—, —CH 2 —NH— or —CH 2 —CH 2 —NH—, 
 an amide group —C(O)—NH—, 
 a sulphonamide group —S(O) 2 —NH—, or 
 a urea group —NHC(O)—NH—, 
 
 B is a substituted or unsubstituted, monocyclic, 5- or 6-membered divalent heteroaryl group, 
 C-D is selected from the following cyclic structures:
 C-D together is a substituted or unsubstituted divalent biphenyl group, 
 C is a substituted or unsubstituted divalent phenyl group and D is a single bond, 
 C is a substituted or unsubstituted divalent phenyl group, and D is a substituted or unsubstituted divalent non-aromatic monocyclic ring which is selected from a saturated or unsaturated divalent cycloalkyl group or a saturated or unsaturated divalent heterocycloalkyl group, 
 C-D together is a spiro residue, wherein
 the first cyclic component is a benzo-fused cyclic component wherein the ring which is fused to the phenyl part is a 5- or 6-membered ring, optionally comprising one or more heteroatoms, the first cyclic component being attached to the moiety B via its phenyl part, and 
 the second cyclic component is a cycloalkyl or cycloalkylidenyl residue which is attached to L2, 
 
 
 L2 is selected from the group consisting of:
 a single bond, 
 a divalent residue having the following structure:
   —[R 1 ] a —[R 2 ] b —[C(O)] c —[N(R 3 )] d —[R 4 ] e —[R 5 ] f —
 
 
 wherein 
 a is 0 or 1, 
 b is 0 or 1, 
 c is 0 or 1, 
 d is 0 or 1, 
 e is 0 or 1, 
 f is 0 or 1, 
 with the proviso that (a+b+c+d+e+f)>0, and c=1 if d=1, 
 R 1 , R 2 , R 4  and R 5 , which can be the same or different, are a substituted or unsubstituted divalent alkyl, cycloalkyl, alkenyl, alkynyl, alkylene, aryl or heterocyclyl residue, 
 R 3  is H or hydrocarbyl, or R 3  and R 4  form together with the nitrogen atom to which they are attached a 5- or 6-membered heterocycloalkyl group, 
 an alkylidenyl group which is linked to the moiety D via a double bond, 
 
   with the proviso that L2 is not —C(O)—[R 4 ] e —[R 5 ] f — when C is a substituted or unsubstituted divalent phenyl group and D is a single bond,
 E is selected from the group consisting of:
 a sulphonic acid group and derivatives thereof, 
 a carboxyl group and derivatives thereof, wherein the carboxyl carbon atom is attached to L2, 
 a phosphonic acid group and derivatives thereof, 
 an alpha-keto hydroxyalkyl group, 
 a hydroxyalkyl group wherein the carbon atom bonded to the hydroxyl group is further substituted with one or two trifluormethyl groups, 
 a substituted or non-substituted five-membered heterocyclyl residue having in the ring at least two heteroatoms and at least one carbon atom, wherein
 the at least one carbon atom of the ring is bonded to two heteroatoms; 
 at least one of the heteroatoms to which the carbon atom of the ring is bonded is a member of the ring; 
 and at least one of the heteroatoms to which the carbon atom of the ring is bonded or at least one of the heteroatoms of the ring is bearing a hydrogen atom; 
 
 
   or a prodrug or a pharmaceutically acceptable salt thereof.   
     
     
         54 . A pharmaceutical compositions comprising:
 i) a compound according to  claim 38 ,   ii) at least one compound selected from
 a) antidiabetic agents, 
 b) hypolipidemic agents, 
 c) anti-obesity agents, 
 d) anti-hypertensive agents, 
 e) agonists of peroxisome proliferator-activator receptors, and 
   iii) one or more pharmaceutically acceptable carriers.   
     
     
         55 . A method for treating conditions or disorders associated with DGAT1 activity, comprising:
 administering to a mammal in need thereof a therapeutically effective amount of a compound of  claim 38 .   
     
     
         56 . The method according to  claim 55 , wherein the disorder is selected from a metabolic disorders such as obesity, diabetes, anorexia nervosa, bulimia, cachexia, syndrome X, insulin resistance, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, and nonalcoholic fatty liver disease; cardiovascular diseases, such as atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis, and vascular stenosis; neoplastic diseases, such as solid tumors, skin cancer, melanoma, lymphoma, and endothelial cancers, for example, breast cancer, lung cancer, colorectal cancer, stomach cancer, other cancers of the gastrointestinal tract (for example, esophageal cancer and pancreatic cancer), prostate cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, and ovarian cancer; dermatological conditions, such as acne vulgaris. In yet another aspect, the present invention provides methods of using a compound or composition of the invention as an anorectic.